

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Paul

INT APP. NO: 10/581,295

FILED: 3/29/2004

FOR: Lupus Antibodies for Passive Immunotherapy of HIV/AIDS

GAU:

EXAMINER:

PTO CONFIRMATION NO. 3691

37 CFR 1.97 INFORMATION DISCLOSURE STATEMENT

ASSISTANT COMMISSIONER FOR PATENTS
ALEXANDRIA, VA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached PTO-1449. Copies of the listed references are being submitted herewith or, were submitted in the parent or grandparent application, where required, as were either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references, or cited by the examiner.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

PETITION

- ☐ Applicant(s) hereby request consideration of the attached information. A check is attached in the amount of the Petition fee required under 37 CFR §1.17(p).

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 50-2106.

31518

PATENT TRADEMARK OFFICE

Respectfully submitted,

02/06/2007

Date

/RobertHahl#33,893/

Robert Hahl
Registration No. 33,893

37 CFR 1.98(A)(1) Reference Citation

NEIFELD IP LAW REFERENCE FORM LIST OF REFERENCES CITED BY THE APPLICANT (Rev: 5/14/2003)	NEIFELD REF: UTEX0010UPCT-US	APPLICATION NO: 10/581,295
	FIRST NAMED INVENTOR: Paul	
	FILING DATE: 3/29/2004	GROUP ART UNIT:

LISTING OF UNITED STATES PATENTS - U series

[illegible]

37 CFR 1.98(A)(1) Reference Citation

LISTING OF UNITED STATES PUBLISHED APPLICATIONS - P Series

[illegible]

37 CFR 1.98(A)(1) Reference Citation

LISTING OF FOREIGN AND INTERNATIONAL PATENT DOCUMENTS - F Series

[illegible]

37 CFR 1.98(A)(1) Reference Citation

LISTING OF NON PATENT LITERATURE - O Series

EXAMINER INITIALS	REFERENCE NUMBER (O Series)	PUBLICATION DATE	INCLUDE IN SEQUENCE: Name of first author (in CAPITAL LETTERS), Title in quotation marks, name of publication, date of publication, page numbers, publisher, city of publication, and country of publication	ENGLISH LANGUAGE TRANSLATION ATTACHED? (YES OR NO) AND/OR OR IDENTIFICATION OF PRIORITY APPLICATION IN WHICH REFERENCE IS CITED
/B.P./	O-001		International Search report, PCT/US04/09399, mailed June 1, 2005.	
	O-002		Written Opinion of the International Searching Authority, PCT/US04/09399, mailed June 1, 2005.	
	O-003		International Search report, PCT/US04/09662, mailed June 28, 2006.	
	O-004		Written Opinion of the International Searching Authority PCT/US04/09662, mailed June 28, 2006.	
	O-005	3/28/2003	Paul et al., "Specific HIV gp 120-cleaving antibodies induced by covalently reactive analog of gp 120. J. Biol. Chem. 30 May 2003, Vol. 278, No. 22, pages 20429-20435.	
	O-006		Nishiyama et al., "Antibodies to the Superantigenic Site of HIV-1 gp 120: Hydrolytic and Binding Activities of the Light Chain Subunit" submitted with application US 60/857,764, filed November 9, 2006.	
	O-007		"Induction of antibodies to the gp120 superantigenic site by administration of protein A" submitted with application US 60/857,764, filed November 9, 2006.	
	O-008		Planque et al., "Naturally Occurring Catalytic IgAs: Protective Anti-HIV Mediators?" submitted with application US 60/857,764, filed November 9, 2006.	
	O-009		Planque et al., "Ontogeny of Proteolytic Immunity: IgM Serine Proteases" submitted with application US 60/534,689, filed January 8, 2004.	
↓	O-010		Karle et al., "Selective IgM-Catalyzed Hydrolysis of HIV gp120: An innate defense against gp120?" submitted with application US 60/534,689, filed January 8, 2004.	

37 CFR 1.98(A)(1) Reference Citation

/B.P./	O-011	12/15/2003	Nishiyama et al., "Toward selective covalent inactivation of pathogenic antibodies" J. Biol. Chem. 27 February 2004, Vol. 279, No. 9, pages 7877-7883.
	O-012		Planque et al., "Broadly Distributed Chemical Reactivity of Natural Antibodies Expressed in Coordination with Specific Antigen Binding Activity" submitted with application in US 60/457,293, filed March 26, 2003.
	O-013		Karle et al., "HIV-1 Neutralizing Antibody Fragments to a Conserved Envelope Determinant from Lupus Libraries" submitted with application in US 60/457,570, filed March 27, 2003.
	O-014	1/2000	Paul et al., "Natural catalytic immunity is not restricted to autoantigenetic substrates: Identification of a human immunodeficiency virus gp 120-cleaving antibody light chain" Appl. Biochem Biotechnol. Jan-Mar 2000, Vol. 83, No. 1-3, pages 71-82.
	O-015	11/7/1994	Pinto et al. "Panel of anti-gp 120 monoclonal antibodies reacts with same nuclear proteins in uninfected cells as those recognized by autoantibodies from patients with systemic lulus erythematosus" Aids Res. And Hum Retroviruses, 1994, Vol. 10, pages 823-828.
	O-016	11/6/1996	Fraziano et al., "Epitope specificity of anti-HIV antibodies in human and murine autoimmune diseases" Aids Research and Human Retroviruses, 1996, Vol. 12, No. 6, pages 491-496.
↓	O-017	1995	Root-Bernstein, "Preliminary evidence for idiotypic-antiidotypic immune complexes cross-reactive with Lymphocyte antigenss in AIDS and lupus" Medical Hypotheses (1995) 44, 20-27.

37 CFR 1.98(A)(1) Reference Citation

/B.P./	O-018	2002	Taguchi et al. "A mechanism-based probe for gp 120-hydrolyzing antibodies" Bioorg. Med. Chem. Lett. 2002, Vol. 12, pages 3167-3170.	

Date: 12/07/2008	Examiner's Signature: /Bo Peng/
------------------	---------------------------------

Printed: May 14, 2003 (3:24pm)

Y:\Clients\University of Texas\UTEX0010\UTEX0010UPCT-US\Drafts\ReferenceCitation_2-2-2007.wpd